At 4.5% CAGR, North America Infectious Disease Therapeutics Market is Projected to be Worth US$ 65,955.97 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the North America infectious disease therapeutics market was valued at US$ 46,376.53 million in 2022 and is projected to reach US$ 65,955.97 million by 2030, registering a CAGR of 4.5% from 2022 to 2030. Rising prevalence of infectious disease and rising number of product approvals and launches are among the critical factors attributed to drive the North America infectious disease therapeutics market growth.
The infectious disease therapeutics market involves many small and big companies. To increase market share, the market players are opting for various strategies, such as new product launches, regional expansion, and advancements. Infectious disease therapeutics are safer and more effective with continued innovation. Therefore, the acceptance of infectious disease therapeutics is increasing among the global population.
A few of the recent developments in the infectious disease therapeutics market are mentioned below:
- In May 2023, The Food and Drug Administration granted full approval to Pfizer's COVID antiviral pill, Paxlovid, for adults who are at high risk of getting severely sick with SARS-CoV-2. Paxlovid is specifically advised for the treatment of mild to moderate COVID-19 infection in adults older than 50 and people who suffer from certain medical conditions that are at a higher risk of being hospitalized or dying.
- In May 2021, Pfizer acquired Amplyx Pharmaceuticals to expand its anti-infective therapies pipeline. With the acquisition, Pfizer has also secured ownership of Amplyx's early-stage pipeline that includes potential antiviral and antifungal therapies. Amplyx's lead compound, Fosmanogepix, is a novel investigational antifungal that is currently under development for the treatment of invasive fungal infections. Fosmanogepix has the potential to target fungal strains resistant to standard-of-care therapy.
- In January 2021, US Food and Drug Administration (FDA) approved CABENUVA (cabotegravir and rilpivirine) by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adolescents who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen-with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.
Thus, the participation of market players in product development and innovation, and an increase in the approvals of drugs are likely to fuel the growth of the infectious disease therapeutics market during the forecast period.
On the contrary, emergence of anti-infective drugs resistance and associated side effects hamper the growth of the North America infectious disease therapeutics market.
Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held 44.3% market share in 2022, amassing US$ 20,527.09 million. It is projected to garner US$ 29,533.71 million by 2030 to register 4.7% CAGR during 2022-2030.
In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held 35.5% share of North America infectious disease therapeutics market in 2022, amassing US$ 16,442.72 million. It is anticipated to garner US$ 24,388.79 million by 2030 to expand at 5.1% CAGR during 2022-2030.
Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held 55.4% market share in 2022, amassing US$ 25,669.52 million. It is projected to garner US$ 37,257.30 million by 2030 to register 4.8% CAGR during 2022-2030.
In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 48.8% share of North America infectious disease therapeutics market in 2022, amassing US$ 22,617.54 million. It is anticipated to garner US$ 32,582.07 million by 2030 to expand at 4.7% CAGR during 2022-2030.
Based on country, the North America infectious disease therapeutics market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.4% share of North America infectious disease therapeutics market in 2022. It was assessed at US$ 38,678.03 million in 2022 and is likely to hit US$ 55,565.08 million by 2030, registering a CAGR of 4.6% during 2022-2030.
Key players operating in the North America infectious disease therapeutics market are AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd, among others.
- In October 2022, During IDWeek 2022, which took place in Washington, D.C. from October 19 to October 23, 2022, Pfizer Inc. presented data from its extensive infectious disease portfolio. This included company-sponsored and collaborative research studies covering both licensed and investigational vaccines, as well as antibiotic and antiviral therapies. Full data from its Phase 3 (NCT05035212) RENOIR clinical study, which examined the administration of its bivalent RSV A and B, stabilized RSV prefusion F subunit vaccine candidate, RSVpreF, to individuals 60 years of age and above, were highlighted in the data.
- In February 2021, BioCryst Pharmaceuticals Inc. reported that the FDA had accepted a supplemental new drug application for RAPIVAB (peramivir injection), allowing patients six months of age and older who have experienced symptoms for no more than two days to be added to the RAPIVAB patient population for the treatment of acute uncomplicated influenza. RAPIVAB has been recommended for patients two years of age and older before this approval.
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com
